Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: A cross-sectional study

Rheumatology (United Kingdom)

Volumn 51, Issue 6, 2012, Pages 1112-1119

  Burt, Morton G ^a,b   Willenberg, Venecia M ^a   Petersons, Carolyn J ^a,b   Smith, Malcolm D ^a,b   Ahern, Michael J ^a,b   Stranks, Stephen N ^a,b  

^a REPATRIATION GENERAL HOSPITAL   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Glucocorticoids; Postprandial hyperglycaemia; Sensitivity and specificity

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOSE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SCREENING TEST; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FEMALE; GLUCOCORTICOIDS; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; MASS SCREENING; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; RHEUMATIC DISEASES; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84861473460     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes003     Document Type: Article

References (38)

1. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids- new mechanisms for old drugs. N Engl J Med 2005;353:1711-23.
2. Walsh LJ, Wong CA, Pringle M et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313:344-6.
3. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in UK over the past 20 years. Rheumatology 2011;50:1982-90.
4. Gorter SL, Bijlsma JW, Cutolo M et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1010-4.
5. Kirwan JR, Bijlsma JW, Boers M et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;1:CD006356.
6. Steen KS, Lems WF, Visman IM et al. High incidence of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68:1509-10.
7. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci 1999;96: 513-23.
8. van Raalte DH, Nofrate V, Bunck MC et al. Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. Eur J Endocrinol 2010;162:729-35.
9. Matsumoto K, Yamasaki H, Akazawa S et al. High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. J Clin Endocrinol Metab 1996; 81:2621-6.
10. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1-12.
11. Caporali R, Cimmino MA, Ferraccioli G et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004;141:493-500.
12. Simmons RK, Rahman M, Jakes RW et al. Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort. Diabetologia 2011; 54:312-9.
13. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004;27(Suppl. 1):S11-4.
14. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006;23: 579-93.
15. Arnaldi G, Angeli A, Atkinson AB et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88:5593-602.
16. Burt MG, Roberts GW, Aguilar-Loza NR et al. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011;96:1789-96.
17. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989;38: 387-95.
18. Abdul-Ghani MA, Jenkinson CP, Richardson DK et al. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 2006;55:1430-5.
19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15: 539-53.
20. Voorrips LE, Ravelli AC, Dongelmans PC et al. A physical activity questionnaire for the elderly. Med Sci Sports Exerc 1991;23:974-9.
21. Esteban NV, Loughlin T, Yergey AL et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 1991;72:39-45.
22. Filipsson H, Monson JP, Koltowska-Haggstrom M et al. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006;91:3954-61.
23. Sherlock M, Reulen RC, Alonso AA et al. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 2009;94: 4216-23.
24. Chiodini I, Morelli V, Salcuni AS et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 2010;95: 2736-45.
25. Gurwitz JH, Bohn RL, Glynn RJ et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97-101.
26. Dasgupta B, Dolan AL, Panayi GS et al. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 1998;37: 189-95.
27. Wassenberg S, Rau R, Steinfeld P et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:3371-80.
28. Hoes JN, Jacobs JW, Verstappen SM et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009;68:1833-8.
29. Burt MG, Johannsson G, Umpleby AM et al. Impact of acute and chronic low-dose glucocorticoids on protein metabolism. J Clin Endocrinol Metab 2007;92: 3923-9.
30. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32: 1327-34.
31. Boronat M, Saavedra P, Lopez-Rios L et al. Differences in cardiovascular risk profile of diabetic subjects discordantly classified by diagnostic criteria based on glycated hemoglobin and oral glucose tolerance test. Diabetes Care 2010;33:2671-3.
32. Kumar PR, Bhansali A, Ravikiran M et al. Utility of glycated hemoglobin in diagnosing type 2 diabetes mellitus: a community-based study. J Clin Endocrinol Metab 2010; 95:2832-5.
33. Hoes JN, van der Goes MC, van Raalte DH et al. Glucose tolerance, insulin sensitivity and {beta}-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 2011;70:1887-94.
34. Darmon P, Dadoun F, Boullu-Ciocca S et al. Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity. Am J Physiol Endocrinol Metab 2006;291:E995-1002.
35. Souverein PC, Berard A, Van Staa TP et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004;90:859-65.
36. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998;21:1236-9.
37. DECODE Study Group; the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161: 397-405.
38. van Raalte DH, Brands M, van der Zijl NJ et al. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia 2011;54:2103-12.